Nkarta, Inc. (NKTX): Capital Expenditures
$1.21M
Year ended 2025-12-31
$1.15M
Trailing 12 months to 2026-06-30
-70.5%
3-year compound annual growth
-30.6%
5-year compound annual growth
| Period ended | Capital Expenditures | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $1.21M | -72.6% | 2026-03-25, From 2025-01-01 |
| 2024-12-31 | $4.41M | -84.3% | 2026-03-25, From 2024-01-01 |
| 2023-12-31 | $28.15M | -40.3% | 2025-03-26, From 2023-01-01 |
| 2022-12-31 | $47.11M | +837.5% | 2024-03-21, From 2022-01-01 |
| 2021-12-31 | $5.03M | -33.1% | 2023-03-16, From 2021-01-01 |
| 2020-12-31 | $7.51M | +289.6% | 2022-03-17, From 2020-01-01 |
| 2019-12-31 | $1.93M | n/a | 2021-03-25, From 2019-01-01 |
Capital Expenditures at similar companies
| Company | Year ended | Capital Expenditures | Change YoY |
|---|---|---|---|
| Nkarta, Inc. (NKTX) | 2025-12-31 | $1.21M | -72.6% |
| Abbott Laboratories (ABT) | 2025-12-31 | $2.17B | -1.6% |
| Bristol Myers Squibb Co (BMY) | 2025-12-31 | $1.31B | +5.0% |
| Eli Lilly & Co (LLY) | 2025-12-31 | $7.84B | +55.0% |
| Pfizer Inc (PFE) | 2025-12-31 | $2.63B | -9.6% |
| Johnson & Johnson (JNJ) | 2025-12-28 | $4.83B | +9.2% |
| Nature's Sunshine Products Inc (NATR) | 2025-12-31 | $6.48M | -40.9% |
| Merck & Co., Inc. (MRK) | 2025-12-31 | $4.11B | +21.9% |
| Lisata Therapeutics, Inc. (LSTA) | 2025-12-31 | $28.0K | n/a |
Compare NKTX, ABT, BMY, LLY side by side · Screen every company in Pharmaceutical Preparations ↗